SNSE senseibio.com: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Sensei Biotherapeutics (SNSE) develops personalized tumor vaccines, claiming pricing power due to its unique method of immune stimulation. However, a lack of sales and high innovation costs are leading to capital depletion. Meanwhile, antibody development remains independent of economic cycles. A retrospective of the share price with an EV/EBITDA ratio of 0.00 confirms the high macro-resilience of the business during the R&D stage.

Sensei Biotherapeutics Inc - Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan SNSE (periode 23.11.2025 - 16.06.2026)

Ringkesan rincian data analitis senseibio.com (SNSE)

- rega saham lan target rega konsensus:

Kutipan saham Sensei Biotherapeutics, Inc.|SNSE - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar SNSE|SNSE - Nilai Dipunlarasaken Utang lan Kas

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Sensei Biotherapeutics|SNSE - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku senseibio.com|SNSE - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang marang Ekuitas Sensei Biotherapeutics|SNSE - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Sensei Biotherapeutics, Inc.|SNSE - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku SNSE|SNSE - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Sensei Biotherapeutics|Indikator likuiditas cepet senseibio.com

- rincian asil keuangan lan kelipatan valuasi:

SNSE - Bathi resik taunan|Bathi mangsa ngarep Sensei Biotherapeutics|SNSE - Rasio rega pasar marang bathi resik|Pangali Forward P/E Sensei Biotherapeutics, Inc.|SNSE - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA SNSE|SNSE - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Sensei Biotherapeutics|SNSE - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan senseibio.com|SNSE - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Sensei Biotherapeutics

Analisis fundamental perusahaan:SNSE (Sensei Bio)

Developing innovative cancer vaccines requires significant capital expenditures, making the business valuation sensitive to debt load and tax obligations. The EV/EBITDA ratio for Sensei Biotherapeutics (SNSE) reflects the relationship between the total enterprise value and operating profit before depreciation and amortization, allowing investors to assess the real value of assets relative to their ability to generate cash flow regardless of the financing structure.

Analisis pesaing Sensei Biotherapeutics